Genelux CEO Zindrick sells $91,899 in common stock

Thomas Zindrick, President and CEO of GENELUX Corp (NASDAQ:GNLX), sold common stock valued at $91,899 on August 31, 2026, according to a recent regulatory filing.

The transaction involved the sale of 34,463 shares at prices ranging from $2.59 to $2.81, with a weighted average sale price of $2.6666 per share. The shares were sold to cover estimated taxes in connection with the vesting of restricted stock units. Following this transaction, Mr. Zindrick beneficially owns 1,226,427 shares of GENELUX Corp common stock.The sale comes as GENELUX shares trade at $2.55, down 11% over the past week and 42% year-to-date. According to InvestingPro analysis, the stock appears undervalued at current levels, with one ProTip noting the company holds more cash than debt on its balance sheet. Investors can access 11 additional ProTips and comprehensive financial metrics on the platform.

In other recent news, Genelux Corporation has made significant strides in its cancer therapy program. Benchmark has reiterated its Speculative Buy stock rating for Genelux, maintaining a price target of $20.00. This decision follows the company’s progress in the clinical development of Olvi-Vec, an oncolytic virus-based cancer immunotherapy. Recent Phase 1b/2 data revealed that Olvi-Vec can transform the tumor microenvironment, potentially enhancing the effectiveness of platinum-based chemotherapy. Additionally, Genelux held its 2026 Annual Meeting of Stockholders, where John Smither was elected as a Class I Director. He will serve until the 2029 Annual Meeting or until a successor is appointed. The election saw 8,696,891 votes in favor, with 3,393,408 votes withheld and 16,172,901 broker non-votes. These developments highlight Genelux’s ongoing efforts in both its corporate governance and clinical advancements.